Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease

Abstract Background The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of disease severity. Whilst desirable patterns of cognitive-functional imp...

Full description

Bibliographic Details
Main Author: John E. Harrison
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13195-018-0386-7